FDA Approves Diabetes Self-Monitoring Device

According to the 2011 National Diabetes Fact Sheet, more than 25 million children and adults in the US have diabetes, a number which is only predicted to increase in the future. In response to these rising numbers, a new addition in the fight to manage this disease has recently been approved by the FDA.

PositiveID Corporation has developed a diabetes management system called iglucose, which melds mobile technology with traditional glucose monitoring, allowing patients to monitor their current and logged glucose levels via the same device.

Both the American Diabetes Association and US Centers for Disease Control and Prevention have recommended for years that patients with diabetes monitor and record their glucose readings so that they can show them to their healthcare professionals. Although self-monitoring plays a large role in assessing the efficacy of the patient’s diabetes management regimen, in the past, most patients have not kept consistent and accurate logbooks.

However, by using iglucose, this problem can be solved. PositiveID’s iglucose system is able to transmit data collected on a variety of FDA approved blood glucose meters to a secure database via mobile technology. This allows them to opt-in to automatically share this information with family members, caregivers, and healthcare professionals via text message, email, or fax, without the need for a mobile phone or wireless plan.

PostiveID’s Chief Executive Officer Wiliam J. Caragol stated that the company views iglucose as “… an opportunity to help decrease costs to our healthcare system by helping to improve disease management and patient compliance.” This belief was shared by 76 percent of diabetes educators surveyed by at the AADE annual conference, who said they would recommend iglucose to their patients.

This newly approved diabetes management device is projected to become available within the next couple of months as PositiveID launches initial roll-outs of the product, partnered with AT&T in the US.

This post was written by:

- who has written 59 posts on mHealthWatch.

Contact the author